Page 2 of 19 · 436 questions tagged vendor-vetting.
What I have: a GLP-1 receptor agonist · purity figure. This is presented as though it settles something, and I am not convinced it does. I have two documents that…
Stated plainly: FGP · cagrilintide. This is not behaving the way I expected and I want to understand the discrepancy before I act on it. I have photographed the…
This is my second independent submission on material from the same supplier. I suspect the usual explanation for this is wrong, or at least incomplete. I am aware…
The specifics, since they change the answer: MKM · survodutide. An unexpected observation, and I would like a differential rather than reassurance. The conditions…
I have both a purity figure and a content figure, which is why the discrepancy is visible. I want a method I can write down and repeat, not a rule of thumb. I would…
What I am working with: WXT · mazdutide. This is asserted often enough that I assumed it was established, and then I went looking for the source. I have searched the…
Concretely: 95.2% · liraglutide · ERP. I want to decide this in advance so that I am not deciding it under pressure later. Assume I will follow the plan I write down,…
For reference: 97.9% · ecnoglutide · JEEP. I am at the decision point and I would rather think it through than improvise. I would rather spend money on measurement…
I have both a purity figure and a content figure, which is why the discrepancy is visible. I have the document in front of me and I can read the numbers. What I…
The case in front of me: 98.8% · oral semaglutide · QSC. The failure mode I am trying to avoid is making this decision emotionally. I have twelve months in view and I…
Numbers first: SWB · Qingdao Sigma Chemical. I have used one of these for a while and I am considering switching, which requires a reason. What I care about is…
Conditions: VendorInvestigate · Zhuhai Kerui Biotechnology. The figures are clear enough; the question is what they mean and what they do not. I can supply the…
I am comparing a supplier certificate against an independent result on the same lot. I have read the primary source rather than the summary, which has left me with…
Details up front: 99.4% · retatrutide · GL Biochem. I would rather over-plan the first cycle and simplify later. I am prepared to do the work if someone can tell me…
I have the report as a PDF with the chromatogram on page two, so I can quote specifics. Somebody stated this to me confidently and I would like to check it before…
The method section is present, which is unusual enough that I want to make use of it. This is a procedural question rather than a theoretical one, and I would like…
I have both a purity figure and a content figure, which is why the discrepancy is visible. I would like to understand the steps well enough to explain them to someone…
What I am working with: lot-specific certificate · WWB. I have read the primary source rather than the summary, which has left me with more questions. I understand…
The method section is present, which is unusual enough that I want to make use of it. This has the shape of a fact but I cannot find its origin. What I found instead…
Concretely: 97.9% · tirzepatide · ERP. I want to decide this in advance so that I am not deciding it under pressure later. Assume I will follow the plan I write down,…
Conditions: QST · Zhuhai Kerui Biotechnology. These are treated as interchangeable and I do not think they are. If both are acceptable I would like to know that, so I…
The specifics, since they change the answer: 96.8% · ecnoglutide · WWB. I am at the decision point and I would rather think it through than improvise. I would rather…
The lot number on the vial matches the certificate, which at least rules out the easy problem. The empirical answer seems settled. The explanation does not. If the…
Details up front: 99.4% · dulaglutide · QYB. This is a planning question. I know what my options are; I do not know how to weigh them. What I want is the minimum…